Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/21: The Beginning of the End for QE
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Vical Incorporated ( VICL - Snapshot Report ) recently signed an agreement with Bristol-Myers Squibb Company ( BMY - Analyst Report ) providing the latter with a global, non-exclusive license to its patented platform DNA immunization technology and Vaxfectin adjuvant.
As per the deal, Bristol-Myers will utilize Vical’s technology for the generation of antibodies which have the potential to be used in therapeutic areas for human patients. Vical will also be responsible for the supply of specified quantities of Vaxfectin to Bristol-Myers. However, both parties did not disclose the financial terms of the deal.
Vical Inc. specializes in the research and development of biopharmaceutical drugs which are based on the company’s patented DNA delivery technologies. The DNA delivery technology has the potential to be used for the development of products for the prevention and treatment of life threatening diseases like cancer.
Vical reported that Vaxfectin has showed significant improvement in increasing the efficiency of the immunization process. Vaxfectin, a cationic lipid-based formulation, helps increase a vaccine’s ability to cause immune responses.
We note that apart from the agreement with Bristol-Myers, Vical Inc. also has licensing agreements with other companies related to its patented technologies. Some of these companies are Astellas Pharma Inc., Merck & Co. Inc. ( MRK - Analyst Report ) , Sanofi ( SNY - Analyst Report ) and Aqua Health Ltd. among other biopharmaceutical companies.
The license agreement with Astellas Pharma is for the development and commercialization of the candidate TransVax. TransVax, a first-in-class DNA vaccine, is currently in a late stage study for the prevention of cytomegalovirus (CMV) reactivation in transplant recipients.
Astellas intends to commence a phase III study of TransVax in hematopoietic stem cell transplant (HSCT) recipients in the second half of 2012. The company is also expecting to start a phase II study of TransVax for solid organ transplant (SOT) recipients soon.
Our Recommendation
Currently, we have a Neutral recommendation on Vical Inc. The stock carries a Zacks #3 Rank (short-term ‘Hold’ rating).
Read the full Analyst Report on SNY
Read the full Analyst Report on BMY
Read the full Analyst Report on MRK
Read the full Snapshot Report on VICL